Alivus Life Sciences Declares Q1 FY27 Unaudited Financial Results

Alivus Life Sciences Ltd announced its unaudited financial results for the first quarter ended June 30, 2026. The Board of Directors approved the results in a meeting held on July 30, 2026. The company's results were subjected to a limited review by the statutory auditors. Alivus Life Sciences operates in a single reporting segment: Active Pharmaceutical Ingredient (API). The company also reported an increase in paid-up equity share capital due to the allotment of shares under its Employee Stock Option Scheme.